Federal contract award
HT942525F0013
MONOCLONAL ANTIBODIES FROM KNOCKOUT MICE WHO HAVE BEEN IN-VIVO GENETICALLY IMMUNIZED WITH INTERFERON-ALPHA/BETA RECEPTOR ALPHA CHAIN PROTEIN.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | ARMY MED RES ACQ ACTIVITY |
| NAICS | 325413 — In-Vitro Diagnostic Substance Manufacturing |
| PSC | 6550 — In Vitro Diagnostic Substances, Reagents, Test Kits and Sets |
| Parent award / vehicle | HT942524D0009 |
| Set-aside | Not reported |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $33.1K |
| Current contract value | $33.1K |
| Potential contract value / ceiling | $33.1K |
| Start date | Oct 31, 2024 |
| Current end date | Dec 30, 2024 |
| Potential end date | Dec 30, 2024 |
| Latest award activity | Oct 30, 2024 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Oct 30, 2024 | 0 | $33.1K | MONOCLONAL ANTIBODIES FROM KNOCKOUT MICE WHO HAVE BEEN IN-VIVO GENETICALLY IMMUNIZED WITH INTERFERON-ALPHA/BETA RECEPTOR ALPHA CHAIN PROTEIN. |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.